ArticleLipids in health and disease2026
Unmasking silent bioenergetic failure in normolactatemic AMI patients: a multicenter validation of the TyG-ACAG index.
Article in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundScores such as SOFA and blood lactate, which reflect hemodynamic compromise, may fail to capture early metabolic dysfunction in critically ill patients with Acute Myocardial Infarction (AMI). We aimed to develop and validate the TyG-ACAG index—a novel integrated marker of insulin resistance and metabolic acidosis—and evaluate its incremental value for risk stratification.
methodsThis multicenter, retrospective cohort study was derived in 2,277 adult AMI patients from the eICU-CRD and validated in 738 patients from the MIMIC-IV and Tongji Hospital databases. The TyG-ACAG index was calculated within 24 hours of ICU admission. Associations with all-cause in-hospital mortality were assessed using multivariable logistic regression with Inverse Probability of Treatment Weighting (IPTW). Incremental predictive value over a baseline model (Age + SOFA) was quantified using the Net Reclassification Improvement (NRI). Additionally, we performed discordance analysis and utilized SHAP values from an XGBoost model to interpret feature importance.
resultsA high TyG-ACAG index (>129.45) was independently associated with increased in-hospital mortality (OR = 1.723; 95% CI: 1.343–2.212; P < 0.001). The inclusion of the index significantly refined risk stratification, yielding an NRI of 0.381 (P < 0.001) over the baseline model. Crucially, discordance analysis unmasked a high-risk phenotype: patients with clinically normal lactate (<2.0 mmol/L) but elevated TyG-ACAG levels had significantly higher mortality (HR = 3.95; 95% CI: 2.08–7.48; P < 0.001). Machine learning analysis corroborated these findings, ranking the index as the third most important predictor. Subgroup analysis further highlighted its robust prognostic value, particularly in younger patients (<65 years, OR = 11.84).
conclusionThe TyG-ACAG index serves as a robust indicator of bioenergetic failure, providing prognostic information that complements traditional hemodynamic markers. By identifying high-risk individuals masked by normolactatemia, this novel metric effectively bridges the gap in early metabolic risk assessment for critically ill AMI patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.